The effective tool for self-assessment of adherence to treatment in patients with benign prostatic obstruction and overactive bladder symptoms

References

• Verhamme KM, Dieleman JP, Bleumink GS, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care-the Triumph project. Eur Urol 2002;42:323–8.
   PubMed Web of Science ®Google Scholar
• Castro-Díaz D, Callejo D, Cortés X. Study of Quality of life in Patients with Benign Prostatic Hyperplasia under Treatment with Silodosin. Actas Urol Esp 2014;38:361–6.
   PubMed Web of Science ®Google Scholar
• Cam K, Muezzinoglu T, Aydemir O, et al. Development of a quality of life scale specific for patients with benign prostatic hyperplasia. Int Urol Nephrol 2013;45:339–46.
   PubMed Web of Science ®Google Scholar
• Spångberg A, Dahlgren H. Benign prostatic hyperplasia with bladder outflow obstruction. A systematic review. Lakartidningen 2013;110:682–5.
   PubMedGoogle Scholar
• Liao L, Schaefer W. Qualitative quality control during urodynamic studies with TSPs for cystometry in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int Urol Nephrol 2014;46:1073–9.
   PubMed Web of Science ®Google Scholar
• Efesoy O, Apa D, Tek M, Çayan S. The effect of testosterone treatment on prostate histology and apoptosis in men with late-onset hypogonadism. Aging Male 2016;19:79–84.
   PubMed Web of Science ®Google Scholar
• Demir O, Akgul K, Akar Z, et al. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male 2009;12:29–34.
   PubMed Web of Science ®Google Scholar
• Auffenberg GB, Helfand BT, McVary KT. Established medical therapy for benign prostatic hyperplasia. Urol Clin North Am 2009;36:443–59.
   PubMed Web of Science ®Google Scholar
• Yeh HC, Liu CC, Lee YC, et al. Associations of the lower urinary tract symptoms with the lifestyle, prostate volume, and metabolic syndrome in the elderly males. Aging Male 2012;15:166–72.
   PubMed Web of Science ®Google Scholar
• Yassin A, Nettleship JE, Talib R, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male 2016;19:64–9.
   PubMed Web of Science ®Google Scholar
• Meuleman EJ, Legros JJ, Bouloux PM, Study 43203 Investigators, et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male 2015;18:157–63.
   PubMed Web of Science ®Google Scholar
• Yassin AA, El-Sakka AI, Saad F, Gooren LJ. Lower urinary-tract symptoms and testosterone in elderly men. World J Urol 2008;26:359–64.
   PubMed Web of Science ®Google Scholar
• Lin KH, Lin YW, Wen YC, Lee LM. Efficacy and safety of orally disintegrating tamsulosin tablets in Taiwanese patients with benign prostatic hyperplasia. Aging Male 2012;15:246–52.
   PubMed Web of Science ®Google Scholar
• Salah Azab S, Elsheikh MG. The impact of the bladder wall thickness on the outcome of the medical treatment using alpha-blocker of BPH patients with LUTS. Aging Male 2015;18:89–92.
   PubMed Web of Science ®Google Scholar
• Hanuš T, Zámečník L, Doležal T, et al. Occurrence of overactive bladder in patients with benign prostatic hyperplasia in the Czech Republic. Urol Int 2011;86:407–13.
   PubMed Web of Science ®Google Scholar
• Bosch JL, Bangma CH, Groeneveld FP, Bohnen AM. The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. Eur Urol 2008;53:819–25.
   PubMed Web of Science ®Google Scholar
• Shahab N, Seki N, Takahashi R, et al. The profiles and patterns of detrusor overactivity and their association with overactive bladder symptoms in men with benign prostatic enlargement associated with detrusor overactivity. Neurourol Urodyn 2009;28:953–8.
   PubMed Web of Science ®Google Scholar
• Wada N, Hashizume K, Matsumoto S, Kakizaki H. Dutasteride improves bone mineral density in male patients with lower urinary tract symptoms and prostatic enlargement: a preliminary study. Aging Male 2015;30:1–3.
   Google Scholar
• Kosilov K, Loparev S, Ivanovskaya M, Kosilova L. Randomized controlled trial of cyclic and continuous therapy with trospium and solifenacin combination for severe overactive bladder in elderly patients with regard to patient compliance. Ther Adv Urol 2014;6:215–23.
   PubMedGoogle Scholar
• Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV. effectiveness of solifenacin and trospium for managing of severe symptoms of overactive bladder in patients with benign prostatic hyperplasia. Am J Men′S Health 2016;10:157–63.
   PubMed Web of Science ®Google Scholar
• Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV. A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Arch Gerontol Geriatr 2015;61:212–16.
   PubMed Web of Science ®Google Scholar
• Gopal M, Haynes K, Bellamy SL, Arya LA. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol 2008;112:1311–18.
   PubMed Web of Science ®Google Scholar
• Nichol MB, Knight TK, Wu J, et al. Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol 2009;181:2214.
   PubMed Web of Science ®Google Scholar
• Barkin J. Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability. Patient Prefer Adherence 2011;5:483–90.
   PubMed Web of Science ®Google Scholar
• Ogata I, Yamasaki K, Tsuruda A, et al. Some problems for dosage form based on questionnaire surveying compliance in patients taking tamsulosin hydrochloride. Yakugaku Zasshi 2008;128:291–7.
   PubMed Web of Science ®Google Scholar
• Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns 1999;37:113–24.
   PubMed Web of Science ®Google Scholar
• Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care 1986;24:67–74.
   PubMed Web of Science ®Google Scholar
• Andy UU, Harvie HS, Smith AL, et al. Validation of a self-administered instrument to measure adherence to anticholinergic drugs in women with overactive bladder. Neurourol Urodyn 2015;34:424–8.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Zyczynski T, Margolis MK, et al. Validation of an overactive bladder awareness tool for use in primary care settings. Adv Ther 2005;22:381–94.
   PubMed Web of Science ®Google Scholar
• Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV. Additional correction of OAB symptoms by two anti-muscarinics for men over 50 years old with residual symptoms of moderate prostatic obstruction after treatment with Tamsulosin. Aging Male 2015;18:44–8.
   PubMed Web of Science ®Google Scholar
• Amundsen CL, Parsons M, Cardozo L, et al. Bladder diary volume per void measurements in detrusor overactivity. J Urol 2006;176: 2530–4.
   PubMed Web of Science ®Google Scholar
• Kleinman NL, Odell K, Chen CI, et al. Persistence and adherence with urinary antispasmodic medications among employees and the impact of adherence on costs and absenteeism. J Manag Care Spec Pharm 2014;20:1047–56.
   PubMedGoogle Scholar
• Koneru S, Shishov M, Ware A, et al. Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting. Arthritis Rheum 2007;57:1000–6.
   PubMed Web of Science ®Google Scholar
• Clifford S, Coyne KS. What is the value of medication adherence? J Manag Care Spec Pharm 2014;20:650–1.
   PubMed Web of Science ®Google Scholar